Subtle%20Shapes%20Transparent_edited.png

CASE STUDY

33% REVENUE GROWTH WITH NAMED PATIENT PROGRAM

Case Studies > 33% Revenue Growth with Named Patient Program

How the Head of Global Market Access for an oral oncolytic was able to increase revenue potential by thinking outside the U.S.

SITUATION

U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication.

Forecast in the U.S. was ~ 500 patients.

Challenged to increase revenue potential for the brand.

APPROACH

Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets.

Identified & vetted a vendor with EU & ROW capabilities.

Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs.

RESULTS

By end of year 1, 1/3 of all product sales occurring outside of U.S.

Distribution eventually expanded to multiple markets, including EU, Asia, & South America.

All NPP sales counted toward U.S. revenue (top line).

Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was  approved in ex-U.S. markets.

Pharmaceutical Consultants USA, Europe, Pharmaceutical Consulting Services USA, Europe, Biotech Consultants USA, Europe, Biotech Consulting Services USA, Europe, Pharmaceutical Market Access USA, Europe

SUBSCRIBE

Subscribe to receive news and updates from Archbow Consulting

Pharmaceutical and Biotech Consultancy Services in the USA and Europe

LET'S GET SOCIAL

CONTACT

USA Office

+1 (321) 355-2686

4700 Millenia Blvd., Suite 175, Orlando, FL 32839

Europe Office

+ 41 41 723 23 23

Dammstrasse 19 6300 Zug, Switzerland